FindCure secures over RMB 100M in Series B funding to accelerate development of innovative radiopharmaceutical R&D platform

Recently, FindCure Biotech (Zhongshan) announced the completion of its Series B round of financing, exceeding RMB 100 million. This financing round was co-led by a leading investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharmaceutical. Existing shareholders including Shenglianxin and Renxi Fund also continued to increase their investment. The proceeds will be primarily utilized for the construction of radiopharmaceutical platforms and the advancement of clinical trials, propelling FindCure's development into a new phase.

Radiopharmaceutical conjugates (RDCs) represent an innovative class of precision tumor-targeting drugs. Their structure consists of four core components: a targeting ligand (which specifically recognizes tumor cells), a linker (connecting the targeting ligand to the chelator), a chelator (which stably binds the nuclide), and a radionuclide (which enables diagnosis or therapy). RDCs can directionally deliver radionuclides to tumor tissues, thereby achieving precise diagnosis and treatment of tumors.

Figure 1: Mechanism of Action and Clinical Application of Nuclear Medicine

Radiopharmaceuticals, with their unique diagnostic and therapeutic value, are regarded as a "key enabler of precision medicine" and a "new productive force in the biopharmaceutical industry." They enable the development of products with both diagnostic and therapeutic functions based on the same target, achieving a complete closed loop from precise diagnosis and therapeutic intervention to efficacy evaluation. Currently, the global nuclear medicine market is experiencing rapid growth. According to industry report forecasts, its market size is expected to increase from USD 12.6 billion in 2023 to USD 21.0 billion by 2029.

FindCure is committed to realizing the vision of "Find & Cure." By leveraging its proprietary InnoRDC radiopharmaceutical conjugate research and development platform, the company has built a competitively advanced nuclear medicine technology system. This platform, founded on the team's over three decades of experience in new drug development, systematically regulates the metabolic behavior of drugs in vivo to achieve the ideal characteristics of "high tumor accumulation and rapid kidney clearance," laying the foundation for developing safer and more effective theranostic drugs. In terms of pipeline progress, FindCure has five products that have entered the IIT (Investigator-Initiated Trial) clinical research phase, with clinical studies completed on nearly one hundred cancer patients to date. The pace of its R&D translation and transformation continues to accelerate.

Figure 2: FindCure InnoRDC Platform Technology